Abstract
Background: The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis. No data are currently available on the potential prognostic role of this polymorphism in patients with angiographically proven coronary artery disease (CAD). Hereto we sought to address this issue in a large consecutive cohort of patients undergoing coronary revascularization. Methods: A total of 643 CAD patients who underwent myocardial revascularization were followed for 4.2 years (interquartile range: 2.2-8.1 years). The rates of major cardiac adverse events (death, nonfatal myocardial infarction, and unstable angina) were compared according to the -374T/A RAGE polymorphism. Results: During a median follow-up period of 4.2 years, the study endpoint was reached by 126/643 patients (19.6%). We observed adverse cardiac events in 13.4% of patients with AA, 17.5% of those with AT, and 24.2% of those with TT genotype (p
Original language | English |
---|---|
Pages (from-to) | 320-325 |
Number of pages | 6 |
Journal | Archives of Medical Research |
Volume | 39 |
Issue number | 3 |
DOIs | |
Publication status | Published - Apr 2008 |
Keywords
- Genetics
- Polymorphism
- Prognosis
- Receptor for advanced glycation end products
ASJC Scopus subject areas
- Medicine(all)